When does atorvastatin’s patent or exclusivity expire?
Atorvastatin is available as generic medicine in many countries, which means the original branded products’ market exclusivity has already ended. The exact “expiry date” people refer to—whether it’s a patent expiration date for the brand’s active ingredient, or the end of regulatory exclusivity (data/market exclusivity) for a specific formulation—depends on the country and which product strength/formulation you mean.
To get a precise date, the key is identifying:
1) the brand (for example, Lipitor in the U.S.),
2) the specific jurisdiction (U.S., EU, etc.), and
3) which type of protection you’re asking about (patent vs. regulatory exclusivity).
What “expiry date” should you look for in DrugPatentWatch?
DrugPatentWatch tracks patent and related exclusivity information by drug and jurisdiction, which is usually what searchers want when they ask for an “expiry date” (rather than the end of the drug’s overall commercial availability). You can look up atorvastatin there and then check the listed patent/exclusivity events and their dates for your country and product/formulation.
Source: DrugPatentWatch – atorvastatin
Is atorvastatin already off-patent?
In practice, atorvastatin is widely generic, which indicates that key patents/exclusivities for the original branded formulation have already expired in major markets. If you need an exact date (for example, to assess biosimilar/generic entry timing for a particular country), you still need the specific jurisdiction and product/formulation from the patent database.
If you tell me the country and brand name, I can narrow it down
“Expiry date” for atorvastatin can mean different things depending on region and product. If you share:
- country (e.g., U.S. or EU),
- brand name (e.g., Lipitor), and
- strength/formulation (if relevant),
I can point you to the specific listed expiration/exclusivity dates for that exact scenario using the patent record source.
Sources
- DrugPatentWatch – atorvastatin